AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22574560 — intervention group
Group type: EXPERIMENTAL
Intervention: PIRRT (SLEDD-f)
Number of subjects: 60
Study 19436935 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one telephone-based counseling and mailed education (Motivational interviewing)
Number of subjects: 879
Study 19436935 — intervention group
Group type: COMPARATOR
Intervention: Mailed education
Number of subjects: 879
Study 19077735 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Strength Training (CST) for 6 weeks
Number of subjects: 28
Study 19077735 — intervention group
Group type: COMPARATOR
Intervention: No Core Strength Training (Control)
Number of subjects: 28
Study 16435705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic breast model with pulsating lumps (augmented tactile feedback)
Number of subjects: 48
Study 12618970 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg azithromycin once daily for 3 days
Number of subjects: 60
Study 12618970 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin stearate every 6 hours for 3 days
Number of subjects: 60
Study 12618970 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 60
Study 12618970 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between azithromycin and erythromycin
Number of subjects: 60
Study 10095156 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 8
Study 10095156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8607228 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 2084
Study 8607228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2084
Study 1849732 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 12
Study 1849732 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (160 micrograms kg-1)
Number of subjects: 12
Study 1849732 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron and Lorazepam (combined)
Number of subjects: 12
Study 6303001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg propranolol (Dociton)
Number of subjects: 10
Study 6303001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg metoprolol (Beloc)
Number of subjects: 10
Study 6303001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 10
Study 31418425 — intervention group
Group type: EXPERIMENTAL
Intervention: Call center intervention providing information about MR medications
Number of subjects: 287042
Study 31418425 — intervention group
Group type: EXPERIMENTAL
Intervention: Call center intervention
Number of subjects: 287042
Study 28216282 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitters (smokers who stopped smoking)
Number of subjects: 122
Study 28216282 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers (control group)
Number of subjects: 122
Study 27330284 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE for COPD
Number of subjects: 78
Study 27330284 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study 24518752 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 191
Study 24518752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with virgin olive oil
Number of subjects: 191
Study 24518752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with mixed nuts
Number of subjects: 191
Study 21983476 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills for Improving Distress Intolerance (SIDI)
Number of subjects: 76
Study 21983476 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 76
Study 21983476 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 76
Study 19299533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil (100 mg bid)
Number of subjects: 12
Study 19299533 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tedisamil and verapamil
Number of subjects: 12
Study 19299533 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (180 mg bid)
Number of subjects: 12
Study 19299533 — intervention group
Group type: COMPARATOR
Intervention: Tedisamil and verapamil combination
Number of subjects: 12
Study 19299533 — intervention group
Group type: COMPARATOR
Intervention: Verapamil and tedisamil combination
Number of subjects: 12
Study 18024630 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP regimen
Number of subjects: 0
Study 18024630 — intervention group
Group type: COMPARATOR
Intervention: COPP/ABVD
Number of subjects: 0
Study 18024630 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 0
Study 18024630 — intervention group
Group type: EXPERIMENTAL
Intervention: PET imaging
Number of subjects: 0
Study 16053997 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 48
Study 16053997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (hypertension)
Number of subjects: 48
Study 16053997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (diabetes)
Number of subjects: 48
Study 16053997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (hypertension and diabetes)
Number of subjects: 48
Study 16053997 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects) during HUT
Number of subjects: 48
Study 16053997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (hypertension) during HUT
Number of subjects: 48
Study 16053997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (diabetes) during HUT
Number of subjects: 48
Study 16053997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (hypertension and diabetes) during HUT
Number of subjects: 48
Study 16053997 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects) during reactive hyperemia to DCA
Number of subjects: 48
Study 16053997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (hypertension) during reactive hyperemia to DCA
Number of subjects: 48
Study 16053997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (diabetes) during reactive hyperemia to DCA
Number of subjects: 48
Study 16053997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (hypertension and diabetes) during reactive hyperemia to DCA
Number of subjects: 48
Study 12113382 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol 9 microg twice daily
Number of subjects: 64
Study 12113382 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zafirlukast 20 mg twice daily
Number of subjects: 64
Study 12113382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline 400 mg once daily
Number of subjects: 64
Study 9925123 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber meal (15.7 g fiber) containing barley pasta enriched with beta-glucan
Number of subjects: 11
Study 9925123 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber meal (5.0 g fiber) containing pasta made with wheat flour
Number of subjects: 11
Study 7672999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 800 mg (5 ml) human immunoglobulin (1x/week)
Number of subjects: 42
Study 7672999 — intervention group
Group type: COMPARATOR
Intervention: Panthenol (4x10 ml/day) and nystatin (4 x 1 ml/day)
Number of subjects: 42
Study 2258786 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 0
Study 7234648 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (D) 240 mg
Number of subjects: 12
Study 7234648 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (D)
Number of subjects: 12
Study 7234648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 31446157 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha2-receptor antagonist)
Number of subjects: 118
Study 31446157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 31640990 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine for diabetes management
Number of subjects: 48
Study 28948720 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight management program combined with smoking cessation program (including behavioral counseling and nicotine replacement)
Number of subjects: 330
Study 28948720 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation program alone (comparison group)
Number of subjects: 330
Study 28948720 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking abstinence
Number of subjects: 330
Study 28948720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants who were abstinent at 6 months
Number of subjects: 330
Study 25576215 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-1018
Number of subjects: 328
Study 25576215 — intervention group
Group type: COMPARATOR
Intervention: HBsAg-Eng
Number of subjects: 328
Study 24079281 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (maximum dose of 10 mg for <10 years, 20 mg for older children)
Number of subjects: 198
Study 24079281 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 198
Study 22140514 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet CBT plus weekly telephone follow‐up
Number of subjects: 155
Study 22140514 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet CBT only
Number of subjects: 155
Study 22140514 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly telephone follow‐up only
Number of subjects: 155
Study 22140514 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 155
Study 19549149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioplic (dimethacrylate‐based filling)
Number of subjects: 10
Study 19549149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit (zinc oxide/calcium sulphate‐based cement)
Number of subjects: 10
Study 19549149 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidrion R (glass ionomer cement)
Number of subjects: 10
Study 19549149 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM (zinc oxide/eugenol cement)
Number of subjects: 10
Study 19549149 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidrion R and Bioplic
Number of subjects: 10
Study 17352821 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic right ventricular pacing in pediatric patients with complex congenital heart malformations
Number of subjects: 99
Study 17352821 — intervention group
Group type: COMPARATOR
Intervention: Chronic right ventricular pacing in pediatric patients with or without structural heart disease
Number of subjects: 99
Study 17352821 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic right ventricular pacing
Number of subjects: 99
Study 15569112 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg intravenously
Number of subjects: 25
Study 15569112 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg intravenously
Number of subjects: 25
Study 10994933 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I serum concentration in hypertensive patients with LVH
Number of subjects: 100
Study 10994933 — intervention group
Group type: COMPARATOR
Intervention: Troponin I serum concentration in hypertensive patients without LVH
Number of subjects: 100
Study 10994933 — intervention group
Group type: COMPARATOR
Intervention: Troponin I serum concentration in normal controls
Number of subjects: 100
Study 9142772 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dosing (SDD) of aminoglycosides
Number of subjects: 0
Study 9142772 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily dosing of aminoglycosides
Number of subjects: 0
Study 1728834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 0
Study 6704567 — intervention group
Group type: EXPERIMENTAL
Intervention: Active suction at -80 mmHg
Number of subjects: 45
Study 6704567 — intervention group
Group type: EXPERIMENTAL
Intervention: Active suction at -40 mmHg
Number of subjects: 45
Study 6704567 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater sealed drainage
Number of subjects: 45
Study 6704567 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with side effects during thoracocentesis
Number of subjects: 45
Study 6704567 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 45
Study 30829925 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding self‐management (BSM) intervention
Number of subjects: 60
Study 30829925 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 29428106 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative octreotide (Group II)
Number of subjects: 104
Study 29428106 — intervention group
Group type: COMPARATOR
Intervention: No postoperative octreotide (Group I)
Number of subjects: 104
Study 26089554 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐directed online intervention
Number of subjects: 72
Study 26089554 — intervention group
Group type: COMPARATOR
Intervention: 12‐week wait list (control)
Number of subjects: 72
Study 1430080 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg TB
Number of subjects: 8
Study 1430080 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg TB
Number of subjects: 8
Study 21689179 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of primary canines
Number of subjects: 44
Study 21689179 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics used
Number of subjects: 44
Study 21689179 — intervention group
Group type: COMPARATOR
Intervention: Dental anxiety scale (DAS) assessment
Number of subjects: 44
Study 19553094 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in oat and wheat bread and potato (OWP)
Number of subjects: 20
Study 19553094 — intervention group
Group type: COMPARATOR
Intervention: Rye bread and pasta (RP)
Number of subjects: 20
Study 18482765 — intervention group
Group type: EXPERIMENTAL
Intervention: VH fibrin sealant (FS)
Number of subjects: 150
Study 18482765 — intervention group
Group type: COMPARATOR
Intervention: Sutured closure (SC)
Number of subjects: 150
Study 15727506 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 29
Study 15727506 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 29
Study 15727506 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 29
Study 15727506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12880649 — intervention group
Group type: EXPERIMENTAL
Intervention: Concealment instruction (avoid talking about a certain topic)
Number of subjects: 0
Study 12880649 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition (no concealment instruction)
Number of subjects: 0
Study 10327526 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model prespecified for primary analysis
Number of subjects: 0
Study 10327526 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization-based tests for no treatment effect
Number of subjects: 0
Study 8890801 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 605
Study 8890801 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (medication)
Number of subjects: 605
Study 8890801 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 605
Study 1676361 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids and/or histamine‐2‐receptor antagonists
Number of subjects: 48
Study 1676361 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress ulcer prophylactic therapy titrated to achieve a gastric pH of 3.5 or greater
Number of subjects: 48
Study 1676361 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 48
Study 159425 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10
Study 159425 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 31573379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis Use Disorder (CUD)
Number of subjects: 31272
Study 31573379 — intervention group
Group type: EXPERIMENTAL
Intervention: CUD
Number of subjects: 31272
Study 31573379 — intervention group
Group type: COMPARATOR
Intervention: Anxiety disorders
Number of subjects: 31272
Study 31573379 — intervention group
Group type: COMPARATOR
Intervention: Depressive disorders
Number of subjects: 31272
Study 31573379 — intervention group
Group type: COMPARATOR
Intervention: Tobacco use disorder
Number of subjects: 31272
Study 31159786 — intervention group
Group type: EXPERIMENTAL
Intervention: News stories reported with spin
Number of subjects: 900
Study 31159786 — intervention group
Group type: COMPARATOR
Intervention: News stories reported without spin
Number of subjects: 900
Study 28492279 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 71
Study 28492279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 71
Study 28492279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 71
Study 25765952 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 136
Study 25765952 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DC)
Number of subjects: 136
Study 23268837 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (a prostacyclin analog)
Number of subjects: 125
Study 23268837 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 125
Study 23268837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 21115191 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Second Taste Gel
Number of subjects: 320
Study 21115191 — intervention group
Group type: EXPERIMENTAL
Intervention: Topex
Number of subjects: 320
Study 21115191 — intervention group
Group type: EXPERIMENTAL
Intervention: Zap
Number of subjects: 320
Study 21115191 — intervention group
Group type: EXPERIMENTAL
Intervention: pH7 Gel (neutral fluoride agent)
Number of subjects: 320
Study 21115191 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 320
Study 19900941 — intervention group
Group type: COMPARATOR
Intervention: Single-dose cruciferous diet
Number of subjects: 67
Study 19900941 — intervention group
Group type: COMPARATOR
Intervention: Double-dose cruciferous diet
Number of subjects: 67
Study 19900941 — intervention group
Group type: COMPARATOR
Intervention: Cruciferous-plus-apiaceous diet
Number of subjects: 67
Study 19900941 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1-null/GSTT1-null individuals
Number of subjects: 67
Study 19900941 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cruciferous diet in GSTM1-null/GSTT1-null individuals
Number of subjects: 67
Study 19900941 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose cruciferous diet in GSTM1-null/GSTT1-null men
Number of subjects: 67
Study 19900941 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose cruciferous diet in GSTM1+/GSTT1+ men
Number of subjects: 67
Study 17045665 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial block patients
Number of subjects: 51
Study 17045665 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interatrial block)
Number of subjects: 51
Study 16870070 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol plus magnesium (Mg)
Number of subjects: 100
Study 16870070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no combined study medication)
Number of subjects: 100
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Midtrimester ultrasound (US) imaging
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (HUAM)
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler velocimetry in high-risk pregnancy
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term tocolysis
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-course antenatal corticosteroids (BMZ)
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid-releasing hormone (TRH)
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal fibronectin (fFN)
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal heart rate monitoring (FHRM)
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal blood sampling (FBS)
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: US imaging in late pregnancy
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler velocimetry in low-risk pregnancy
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolysis beyond 7 days
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple course antenatal corticosteroids (BMZ)
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 11
Study 12825002 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram ST-segment analysis
Number of subjects: 11
Study 10427126 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with transcatheter arterial embolization (TAE) and percutaneous ethanol injection (PEI)
Number of subjects: 102
Study 10427126 — intervention group
Group type: COMPARATOR
Intervention: No RT (control group)
Number of subjects: 102
Study 10427126 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with TAE and PEI
Number of subjects: 102
Study 7755070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg/day)
Number of subjects: 1629
Study 7755070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1629
Study 7755070 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 1629
Study 7755070 — intervention group
Group type: COMPARATOR
Intervention: No epidural anesthesia
Number of subjects: 1629
Study 2088025 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin
Number of subjects: 20
Study 2088025 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etretinate
Number of subjects: 20
Study 314119 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 61